Full name
KAFARMA WAGNER-ZAREMBA, MOCZYDŁOWSKI SPÓŁKA JAWNA
uses securityreCAPTCHA
47.73.Z - Retail sale of pharmaceutical products
21.10.Z - Manufacture of basic pharmaceutical products
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
47.74.Z - Retail sale of medical and orthopedic products
47.75.Z - Retail sale of cosmetics and toiletries
47.78.Z - Retail sale of other new products
47.91.Z - Intermediary retail sale, non-specialized
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale | 0,5 | 0,5 | 0,3 | -42,4 |
Gross profit (loss) | 0,6 | 0,5 | 0,3 | -34,8 |
EBITDA | 0,6 | 0,5 | 0,3 | -34 |
Short time liabilities | 1,8 | 2,2 | 2,9 | 33,6 |
Other operating costs | 0 | 0 | 0 | -18,7 |
Equity capital | 0,3 | 0,2 | 0,2 | 39,5 |
Operating profit (EBIT) | 0,6 | 0,5 | 0,3 | -34,8 |
Assets | 2,2 | 2,4 | 3,1 | 31,9 |
Net profit (loss) | 0,6 | 0,5 | 0,3 | -34,8 |
Cash | 0,3 | 0,3 | 0,6 | 61,3 |
Net income from sale | 10,3 | 15,8 | 17,8 | 12,6 |
Liabilities and provisions for liabilities | 1,8 | 2,2 | 2,9 | 31,3 |
Working assets | 2 | 2,2 | 2,7 | 19,9 |
Other income costs | 0,1 | 0 | 0 | 61 877,1 |
Depreciation | 0 | 0 | 0 | -24 |
% | % | % | p.p. | |
Profitability of capital | 171,9 | 279,4 | 130,5 | -148,9 |
Equity capital to total assets | 15,2 | 6,9 | 7,4 | 0,5 |
Gross profit margin | 5,5 | 2,9 | 1,7 | -1,2 |
EBITDA Margin | 5,9 | 3,1 | 1,8 | -1,3 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 63 | 50 | 59 | 9 |
Current financial liquidity indicator | 1.1406669616699219 | 1.0312927961349487 | 0.9252456426620483 | -0,1 |
Net dept to EBITDA | -0.5122196674346924 | -0.6767835021018982 | -1.6835910081863403 | -1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane